Myriad Developing Companion Diagnostic for Cephalon | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics and Cephalon have signed an agreement to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study, Myriad announced after the close of the market Wednesday.

Myriad said it will assess BRCA status in patients before they are enrolled in the study, but provided no other details about the study or Cephalon's candidate molecule. Financial and other terms of the agreement also were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.